JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds
JHS Svendgaard Laboratories Ltd · Others (Uncategorized) · 03 Nov 2026, 12:27 am
JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds JHS Svendgaard Laboratories Limited disclosed shareholder-approved modifications, dated 29th Jul'26, regarding the utilization of ₹29.99 crore raised via a preferential issue on 4th Jun'24. For the quarter ended 30th Sep'26, capital expenditure and business expansion allocation was increased from ₹5.9999 crore to ₹11.7499 crore (₹8.4946 crore utilized), while group entity infusion was revised down to ₹10.75 crore for strategic and growth initiatives (₹9.625 crore utilized). General corporate purpose allocation remained unchanged at ₹7.50 crore and is fully utilized. Zero deviation was reported against the modified objects.
Original exchange filing (PDF)
More announcements from JHS Svendgaard Laboratories Ltd
- Un-Audited Financial Results for the Quarter and Half year Ended 30th September, 2026. · 04 Nov 2026
- Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2026 · 04 Nov 2026
- Board of Directors approved the appointment of Mr. Pardeep Kumar Bhardwaj as an Additional Non-Executive Independent Director of the Company. · 03 Nov 2026
- Board of Directors in their meeting dated 02 November, 2026 approved the unaudited Standalone and Consolidated financials for quarter and half year ended 30 September, 2026. · 03 Nov 2026
- JHS Svendgaard Laboratories Limited has submitted to the Exchange, Un-audited-financial results for the period ended September 30, 2026. · 02 Nov 2026
- Board of Directors approved the unaudited standalone and consolidated financials for quarter and half year ended 30 September, 2026. · 02 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 02 Nov 2026
- JHS SVENDGAARD LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 02 Nov 2026
